Progenics Pharma (PGNX) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
- RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
